Long-term switching between ranibizumab and aflibercept in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy

被引:0
作者
Jae Hui Kim
Jong Woo Kim
Chul Gu Kim
Dong Won Lee
机构
[1] Kim’s Eye Hospital,Department of Ophthalmology
来源
Graefe's Archive for Clinical and Experimental Ophthalmology | 2020年 / 258卷
关键词
Age-related macular degeneration; Choroidal neovascularization; Polypoidal choroidal vasculopathy; Switching; Ranibizumab; Aflibercept;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1677 / 1685
页数:8
相关论文
共 263 条
[1]  
Rosenfeld PJ(2006)Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419-1431
[2]  
Brown DM(2006)Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 1432-1444
[3]  
Heier JS(2007)An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 566-583
[4]  
Boyer DS(2010)A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact Ophthalmology 117 2134-2140
[5]  
Kaiser PK(2009)Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy Am J Ophthalmol 148 70-78
[6]  
Chung CY(2010)Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab Am J Ophthalmol 150 666-673
[7]  
Kim RY(2014)Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response Br J Ophthalmol 98 188-194
[8]  
Brown DM(2012)Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab Br J Ophthalmol 96 21-23
[9]  
Kaiser PK(2012)Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration Ophthalmology 119 2537-2548
[10]  
Michels M(2012)Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 154 222-226